Entrada Therapeutics, Inc. (TRDA)
5.25
+0.56
(+11.94%)
USD |
NASDAQ |
Nov 10, 16:00
5.255
0.00 (0.00%)
After-Hours: 20:00
Entrada Therapeutics Enterprise Value : 59.84M for Nov. 10, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 10, 2026 | 59.84M |
| November 09, 2026 | 37.91M |
| November 06, 2026 | 45.74M |
| November 05, 2026 | 32.43M |
| November 04, 2026 | 52.40M |
| November 03, 2026 | 39.09M |
| November 02, 2026 | 54.36M |
| October 30, 2026 | 31.84M |
| October 29, 2026 | 26.56M |
| October 28, 2026 | 43.79M |
| October 27, 2026 | 26.95M |
| October 26, 2026 | 40.26M |
| October 23, 2026 | 26.95M |
| October 22, 2026 | 39.48M |
| October 21, 2026 | 36.35M |
| October 20, 2026 | 49.66M |
| October 19, 2026 | 43.00M |
| October 16, 2026 | 25.38M |
| October 15, 2026 | 41.44M |
| October 14, 2026 | 32.43M |
| October 13, 2026 | 44.57M |
| October 12, 2026 | 69.62M |
| October 09, 2026 | 76.28M |
| October 08, 2026 | 70.80M |
| October 07, 2026 | 73.93M |
| Date | Value |
|---|---|
| October 06, 2026 | 66.49M |
| October 05, 2026 | 68.84M |
| October 02, 2026 | 64.93M |
| October 01, 2026 | 76.67M |
| September 30, 2026 | 102.90M |
| September 29, 2026 | 69.28M |
| September 28, 2026 | 67.73M |
| September 25, 2026 | 65.39M |
| September 24, 2026 | 67.73M |
| September 23, 2026 | 78.63M |
| September 22, 2026 | 86.80M |
| September 21, 2026 | 84.08M |
| September 18, 2026 | 88.36M |
| September 17, 2026 | 94.20M |
| September 16, 2026 | 93.81M |
| September 15, 2026 | 93.42M |
| September 14, 2026 | 100.04M |
| September 11, 2026 | 90.31M |
| September 10, 2026 | 75.51M |
| September 09, 2026 | 102.38M |
| September 08, 2026 | 118.34M |
| September 04, 2026 | 103.16M |
| September 03, 2026 | 104.72M |
| September 02, 2026 | 109.78M |
| September 01, 2026 | 100.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Prime Medicine, Inc. | 722.28M |
| Arrowhead Pharmaceuticals, Inc. | 6.690B |
| Oncolytics Biotech, Inc. | 43.92M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 1.935B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.74M |
| Revenue (Quarterly) | 0.905M |
| Total Expenses (Quarterly) | 40.65M |
| EPS Diluted (Quarterly) | -0.9379 |
| Gross Profit Margin (Quarterly) | 22.65% |
| Profit Margin (Quarterly) | -4.39K% |
| Earnings Yield | -73.17% |
| Normalized Earnings Yield | -73.17 |